LUXEMBOURG / May 08, 2024 / Business Wire / Auna S.A. (NYSE: AUNA) (“Auna” or “the Company”), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its First Quarter 2024 financial results.
Earnings Release
Wednesday, May 22, 2024
Time: After Market Close
Conference Call
Wednesday, May 22, 2024
Time: 5:00 p.m. ET
Quiet Period
Wednesday, May 8 through Wednesday, May 22, 2024
To participate, please dial
+1 888 596 4144 (Toll-Free)
+1 646 968 2525 (International)
Entry Passcode: 3884034
Webcast: click here
About Auna
Auna is a Latin American healthcare company with operations in Mexico, Peru and Colombia, prioritizing prevention and concentrating on high complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish Speaking Americas. Founded in 1989, Auna has built one of Latin America´s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of December 31, 2023, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,308 beds, and 1.3 million healthcare plans.
For more information visit www.aunainvestors.com
Last Trade: | US$6.83 |
Daily Change: | 0.17 2.55 |
Daily Volume: | 10,282 |
Market Cap: | US$204.900M |
November 19, 2024 August 21, 2024 May 22, 2024 March 22, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB